Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Kylie Jenner sued by 2nd ex-housekeeper alleging workplace discrimination

May 1, 2026

Amazon’s built-in AI price history expands to show the entire last year

May 1, 2026

GuardHouse Camera Analyzed: All You Need To Know About the GuardHouse Watch Eye

May 1, 2026

Shippers ‘losing faith’ in CBSA tech systems amid ongoing outages, glitches

May 1, 2026

Neither Norway nor Singapore: Decoding Canada’s new sovereign wealth fund

May 1, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » ZI Class Action Alert – Shareholder Rights Law Firm Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the ZoomInfo Technologies, Inc. Class Action Lawsuit
Press Release

ZI Class Action Alert – Shareholder Rights Law Firm Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the ZoomInfo Technologies, Inc. Class Action Lawsuit

By News RoomSeptember 16, 20243 Mins Read
ZI Class Action Alert – Shareholder Rights Law Firm Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the ZoomInfo Technologies, Inc. Class Action Lawsuit
Share
Facebook Twitter LinkedIn Pinterest Email

SAN DIEGO, Sept. 16, 2024 (GLOBE NEWSWIRE) —

Robbins LLP informs investors that a shareholder filed a class action on behalf of all purchasers of ZoomInfo Technologies, Inc. (NASDAQ: ZI) Class A common stock between November 10, 2020 and August 5, 2024. ZoomInfo is a software and data company that provides customer analytics and intelligence to sales and marketing teams.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that ZoomInfo Technologies, Inc. (ZI) Misled Investors Regarding Demand for its Product

According to the complaint, during the class period, defendants failed to disclose to investors: (a) that ZoomInfo’s financial and operational results during the Class Period had been temporarily inflated by the ephemeral effects of the COVID-19 pandemic, which had pulled-forward demand for the Company’s database of digital contact information; (b) that material portions of ZoomInfo’s existing customer base were attempting to either substantially reduce their use of the Company’s product or abandon it altogether; (c) that ZoomInfo had used manipulative and coercive auto-renew policies and threats of litigation to force customers into remaining with the Company for an additional contractual term even though they did not want to; (d) that ZoomInfo’s coercive customer retention tactics had materially damaged the Company’s customer relationships, client franchise, and competitive advantages, and created a hidden demand cliff for costumer contract renewals in future periods; (e) that ZoomInfo’s reported accounts receivable were materially comprised of debts owed by high-risk small business customers that had a high likelihood of non-payment and had been induced to transact with the Company through a credit program the Company implemented in 2022; (f) that ZoomInfo’s allowance for credit losses was materially inadequate and understated the risk of non-payments by the Company’s customers; and (g) that as a result of (a)–(f), above, ZoomInfo’s reported revenues, operating income, and customer and retention metrics were materially overstated.

As a result, the price of ZoomInfo Class A common stock declined from a class period high of over $79 per share to just $8 per share by the end of the class period, a 90% decline. Further, Defendants, sold billions of dollars’ worth of ZoomInfo stock at artificially inflated prices before the truth was revealed.

What Now: You may be eligible to participate in the class action against ZoomInfo Technologies, Inc. Shareholders who want to serve as lead plaintiff for the class must submit their application to the court by November 4, 2024. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.  

About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against ZoomInfo Technologies, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1cfa0f39-b1c3-45c9-81de-ad0d12d01698

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

GuardHouse Camera Analyzed: All You Need To Know About the GuardHouse Watch Eye

Bevacizumab Biosimilars Market Trastuzumab Biosimilars Market Analysis Report 2026: $2.42 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

B2BROKER Group Puts AI at the Core of B2TRADER as Technology Enters a New Era

Adalimumab, Infliximab and Etanercept Biosimilars Trastuzumab Biosimilars Research Report 2026: $8.05 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2035

Whitespace Makes Iris, AI Intelligence Analysis Agent, Generally Available to Authorized DoW and IC Users

Based Eggman Announces Stage 3 Presale Progress

Systemic Mastocytosis (SM) Treatment Market 2026-2035: Industry to More Than Double in Size, Led by Sanofi, AdvaCare Pharma, and Cogent Biosciences

Investment Banking and Trading Services Market Analysis Report 2026: Bulge-Bracket Banks vs. Elite Boutiques

Shares, Opportunities and Strategies in the $1.7 Billion Ice Cream Maker Market, 2026-2035

Editors Picks

Amazon’s built-in AI price history expands to show the entire last year

May 1, 2026

GuardHouse Camera Analyzed: All You Need To Know About the GuardHouse Watch Eye

May 1, 2026

Shippers ‘losing faith’ in CBSA tech systems amid ongoing outages, glitches

May 1, 2026

Neither Norway nor Singapore: Decoding Canada’s new sovereign wealth fund

May 1, 2026

Latest News

Bevacizumab Biosimilars Market Trastuzumab Biosimilars Market Analysis Report 2026: $2.42 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

May 1, 2026

B2BROKER Group Puts AI at the Core of B2TRADER as Technology Enters a New Era

May 1, 2026

Adalimumab, Infliximab and Etanercept Biosimilars Trastuzumab Biosimilars Research Report 2026: $8.05 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2035

May 1, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version